Literature DB >> 21114921

Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.

Yong Chen1, Jing Zuo, Ying Liu, Hong Gao, Wei Liu.   

Abstract

BACKGROUND AND
OBJECTIVE: miRNA-200c can not only inhibit the aggressiveness of cancer cells but also increase the sensitivity of cells to antitumor drugs. However, some mechanisms are still unclear. Recent researches revealed that E-cadherin is more than an inhibitor of metastasis, and it also plays important roles in reversing drug resistance. We had previously found that miRNA-200c could not only induce the expression of E-cadherin but also increase the sensitivity of gastric cancer SGC7901/DDP cells to cisplatin (DDP). This study aimed to explore the effects of miRNA-200c on biological characteristics of SGC7901/DDP cells and the roles of E-cadherin in the regulatory pathway of miRNA-200c.
METHODS: SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot.
RESULTS: The miRNA-200c expression in SGC7901/DDP cells after transfection of Pre-200c was 7.128 ± 0.159 times of that in negative control (P < 0.05). The IC50 of DDP, 5-FU, paclitaxel, and ADR in Pre-200c-transfected group were significantly lower than that in negative control group (P < 0.05). Compared to the control group, cell proliferation was significantly decreased (P < 0.05). The relative protein expressions of E-cadherin and Bax in Pre-200c-transfected group were significantly higher than those in negative control group (P < 0.05), whereas Bcl-2 was significantly lower than that in control (P < 0.05). Additionally, E-cadherin protein expression was significantly inhibited after transfected with E-cadherin siRNA in SGC7901 cells. The Bax protein expression was significantly down-regulated by E-cadherin siRNA (P < 0.05), whereas the Bcl-2 expression was significantly up-regulated (P < 0.05).
CONCLUSION: miRNA-200c can indirectly regulate apoptosis through E-cadherin in SGC7901/DDP cells, which may be a possible mechanism of miRNA-200c in reversing drug resistance and inhibiting proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114921     DOI: 10.5732/cjc.010.10236

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  10 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A.

Authors:  Binbin Zhang; Yuan Yin; Yaling Hu; Jiwei Zhang; Zehua Bian; Mingxu Song; Dong Hua; Zhaohui Huang
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

3.  Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.

Authors:  Xinli Huang; Jianjie Qin; Sen Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 4.  Clinical application of microRNA in gastric cancer in Eastern Asian area.

Authors:  Ming Gao; Hao Yin; Zhe-Wei Fei
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

Review 5.  Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-10-13

Review 6.  Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer.

Authors:  Ying Liu; Xiang Ao; Guoqiang Ji; Yuan Zhang; Wanpeng Yu; Jianxun Wang
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

7.  The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.

Authors:  Sophie Rae; Cathy Spillane; Gordon Blackshields; Stephen F Madden; Joanne Keenan; Britta Stordal
Journal:  Hum Cell       Date:  2022-07-06       Impact factor: 4.374

8.  Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.

Authors:  Ning Chen; Hye Sook Chon; Yin Xiong; Douglas C Marchion; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Jennifer Permuth-Wey; Robert M Wenham; Sachin M Apte; Jin Q Cheng; Thomas A Sellers; Johnathan M Lancaster
Journal:  Oncol Rep       Date:  2013-11-13       Impact factor: 3.906

9.  MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer.

Authors:  Min Li; Kangsheng Gu; Wei Liu; Xiaoque Xie; Xiaolu Huang
Journal:  Oncotarget       Date:  2017-04-13

Review 10.  Noncoding RNAs in gastric cancer: implications for drug resistance.

Authors:  Ling Wei; Jujie Sun; Nasha Zhang; Yan Zheng; Xingwu Wang; Liyan Lv; Jiandong Liu; Yeyang Xu; Yue Shen; Ming Yang
Journal:  Mol Cancer       Date:  2020-03-19       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.